Trump Administration Reclassifies Medical Marijuana, Granting Tax Breaks and Research Access

On April 23, 2026, acting Attorney General Todd Blanche signed an order that reclassifies state-licensed medical marijuana as a Schedule III substance, a significant downgrade from its previous Schedule I status. This shift marks a historic change in federal cannabis policy, which for decades has treated marijuana on par with heroin and other drugs deemed to have no medical use and high potential for abuse.

The new classification does not legalize marijuana under federal law, but it does ease regulatory burdens substantially. State-licensed medical marijuana producers and distributors can now register with the Drug Enforcement Administration under an expedited system. Importantly, these businesses gain the ability to deduct normal business expenses on their federal taxes, a major financial benefit that advocates hail as overdue recognition of cannabis as medicine.

Blanche framed the decision as fulfilling President Trump’s directive to expand Americans’ access to medical treatment options. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” Blanche said in a statement.

This reclassification also protects researchers from penalties when studying state-licensed marijuana or marijuana-derived products, potentially accelerating scientific understanding of cannabis. The administration has set a hearing to consider broader marijuana reclassification beginning in late June.

Despite these changes, marijuana and marijuana-derived products that are not distributed through state medical programs remain Schedule I drugs, maintaining strict federal controls on recreational and unlicensed cannabis.

The move comes after years of states pushing ahead with their own marijuana laws—40 states now have medical marijuana programs, and 24 plus Washington D.C. have legalized recreational use. Yet federal law has lagged, continuing to criminalize marijuana use and complicate research and business operations.

Critics of the administration’s action, such as Kevin Sabet of Smart Approaches to Marijuana, slammed the order as a “tax break to Big Weed” that sends mixed messages about marijuana’s risks. Sabet warned that policy is increasingly shaped by industry insiders rather than public health concerns.

The Trump administration’s reclassification bypassed the usual lengthy DEA review process by invoking a legal provision allowing the attorney general to adjust drug schedules under international treaty obligations. This shortcut has raised eyebrows about the transparency and motivations behind the decision.

While some Republicans remain firmly opposed to loosening marijuana laws, this policy shift signals a notable break from the hardline federal stance on cannabis that has persisted for nearly a century. The practical effects for patients, businesses, and researchers could be profound, but the move also underscores the fragmented and often contradictory nature of U.S. drug policy.

As states continue to push forward with legalization and medical programs, federal policy remains a patchwork of old prohibitions and new accommodations. The Trump administration’s reclassification of medical marijuana is a historic step, but it leaves many questions unanswered about the future of cannabis regulation in America.